Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma NetworkMartin Dreyling, Eva Hoster, Melania Celli et al.|The Lancet|2024Cited by 135
137 | IBRUTINIB ADDED TO MCL TREATMENT HAS STRONG IMPACT ON MRD RESPONSE AND DISEASE KINETICS: RESULTS FROM THE TRIANGLE TRIALMouhamad Khouja, Christiane Pott, Christa Homburg et al.|Hematological Oncology|2025Cited by 1